22 citations
,
October 2021 in “Dermatologic Therapy” This study found that approximately one-quarter of post-COVID-19 patients experienced telogen effluvium, with a higher incidence among women, hospitalized patients, and those with hypertension or respiratory symptoms.
39 citations
,
August 2021 in “JAAD International” This study found that telogen effluvium and trichodynia are common in patients after COVID-19, and their severity may be influenced by the severity of the COVID-19 infection.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
18 citations
,
April 2021 in “Experimental Dermatology” This study in Italy observed telogen effluvium and trichodynia as common hair-related complications following COVID-19 infection, raising questions about underlying hair follicle biology and potential receptor involvement.
44 citations
,
January 2021 in “Dermatologic Therapy” This study suggests that COVID-19 infection may trigger telogen effluvium, a condition of hair shedding, though medication side effects and pandemic-related stress cannot be excluded as contributing factors.
14 citations
,
December 2020 in “Journal of The American Academy of Dermatology” This study observed a significant increase in telogen effluvium cases among people of color during the COVID-19 pandemic in NYC, notably affecting Hispanic/Latinx individuals.
58 citations
,
November 2020 in “International Journal of Dermatology” COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.
51 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.
35 citations
,
November 2020 in “Dermatologic Therapy” This case series reports telogen effluvium in three patients following severe Sars-Cov-2 infection and suggests a potential association that merits further investigation.
43 citations
,
July 2020 in “Dermatologic Therapy” This study observed a significant increase in certain dermatologic conditions a month and two months after the onset of the COVID-19 pandemic in Turkey, which may suggest a link with asymptomatic COVID-19 infection.
40 citations
,
May 2020 in “Cureus” This review discusses the causes, diagnosis, and treatment of telogen effluvium and reports no new clinical findings; the authors underscore the importance of identifying and eliminating causative factors.
31 citations
,
May 2020 in “Dermatologic Therapy” Quarantine stress likely worsened hair loss in women, but video consultations helped manage their condition and reduce anxiety.
119 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.
31 citations
,
January 2016 in “Drugs - Real World Outcomes” This review discusses the potential link between direct oral anticoagulants and hair loss, suggesting DOACs may not be a suitable alternative for patients with alopecia from traditional anticoagulants; however, no clinical results are reported.
162 citations
,
August 2004 in “Journal of Investigative Dermatology” This study suggests that stress negatively affects hair growth by inducing inflammation and early hair cycle transitions in mice, which might inform strategies for managing stress-related hair loss in humans.
69 citations
,
March 1993 in “Archives of Dermatology” This article proposes five mechanisms for telogen effluvium based on changes in the follicular cycle, which are supported by clinical findings, highlighting the condition's diverse causes.
214 citations
,
March 1993 in “Archives of Dermatology” This article proposes five different mechanisms for telogen effluvium, supported by clinical findings, based on changes in different phases of the hair cycle.
